This is a single arm, multicenter study which will recruit about 40 patients in China.~The study is designed to evaluate the efficacy and safety of furmonertinib in the first-line treatment of patients with EGFR mutations in advanced NSCLC with CNS metastases.~Furmonertinib is a third generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets multiple Epidermal Growth Factor Receptor (EGFR) mutations. It will be administered orally at a dose of 160 mg per time, Q.D.
EGFR mutation positive advanced NSCLC patients with CNS metastases have poor prognosis, second-line furmonertinib dose at 160mg level in EGRF T790M mutation positive CNS metastatic NSCLC have provided relevant benefit with a high CNS PFS and CNS ORR. Whether CNS metastatic EGFR mutation positive NSCLC patients can benefit from first-line furmonertinib 160mg per day has not been reported. This study aims to investigate the efficacy and safety of furmonertinib 160mg per day in CNS metastatic EGFR mutant patients under first-line treatment of advanced NSCLC setting.